These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38878767)

  • 21. Rare Variants in Triglycerides-Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome.
    Paquette M; Amyot J; Fantino M; Baass A; Bernard S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3473-e3482. PubMed ID: 34019660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
    Rocha NA; East C; Zhang J; McCullough PA
    Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etiology and emerging treatments for familial chylomicronemia syndrome.
    Spagnuolo CM; Hegele RA
    Expert Rev Endocrinol Metab; 2024 Jul; 19(4):299-306. PubMed ID: 38866702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.
    Witztum JL; Gaudet D; Arca M; Jones A; Soran H; Gouni-Berthold I; Stroes ESG; Alexander VJ; Jones R; Watts L; Xia S; Tsimikas S
    J Clin Lipidol; 2023; 17(3):342-355. PubMed ID: 37100699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Updates in Drug Treatment of Severe Hypertriglyceridemia.
    Gouni-Berthold I; Schwarz J; Berthold HK
    Curr Atheroscler Rep; 2023 Oct; 25(10):701-709. PubMed ID: 37642858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Volanesorsen for treatment of patients with familial chylomicronemia syndrome.
    Warden BA; Duell PB
    Drugs Today (Barc); 2018 Dec; 54(12):721-735. PubMed ID: 30596391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolism and Disposition of Volanesorsen, a 2'-
    Post N; Yu R; Greenlee S; Gaus H; Hurh E; Matson J; Wang Y
    Drug Metab Dispos; 2019 Oct; 47(10):1164-1173. PubMed ID: 31350288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
    Reeskamp LF; Tromp TR; Stroes ESG
    Curr Opin Lipidol; 2020 Jun; 31(3):140-146. PubMed ID: 32324598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy.
    Lightbourne M; Startzell M; Bruce KD; Brite B; Muniyappa R; Skarulis M; Shamburek R; Gharib AM; Ouwerkerk R; Walter M; Eckel RH; Brown RJ
    J Clin Lipidol; 2022; 16(6):850-862. PubMed ID: 36195542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.
    Tardif JC; Karwatowska-Prokopczuk E; Amour ES; Ballantyne CM; Shapiro MD; Moriarty PM; Baum SJ; Hurh E; Bartlett VJ; Kingsbury J; Figueroa AL; Alexander VJ; Tami J; Witztum JL; Geary RS; O'Dea LSL; Tsimikas S; Gaudet D
    Eur Heart J; 2022 Apr; 43(14):1401-1412. PubMed ID: 35025993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apolipoprotein C-III: going back to the future for a lipid drug target.
    Huff MW; Hegele RA
    Circ Res; 2013 May; 112(11):1405-8. PubMed ID: 23704213
    [No Abstract]   [Full Text] [Related]  

  • 32. Molecular and functional characterization of familial chylomicronemia syndrome.
    Teramoto R; Tada H; Kawashiri MA; Nohara A; Nakahashi T; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
    Atherosclerosis; 2018 Feb; 269():272-278. PubMed ID: 29153744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia.
    Karwatowska-Prokopczuk E; Tardif JC; Gaudet D; Ballantyne CM; Shapiro MD; Moriarty PM; Baum SJ; Amour ES; Alexander VJ; Xia S; Otvos JD; Witztum JL; Tsimikas S;
    J Clin Lipidol; 2022; 16(5):617-625. PubMed ID: 35902351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel mutation in GPIHBP1 causes familial chylomicronemia syndrome.
    Paquette M; Hegele RA; Paré G; Baass A
    J Clin Lipidol; 2018; 12(2):506-510. PubMed ID: 29452893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.
    Blom DJ; O'Dea L; Digenio A; Alexander VJ; Karwatowska-Prokopczuk E; Williams KR; Hemphill L; Muñiz-Grijalvo O; Santos RD; Baum S; Witztum JL
    J Clin Lipidol; 2018; 12(5):1234-1243.e5. PubMed ID: 30318066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
    Falko JM
    Endocr Pract; 2018 Aug; 24(8):756-763. PubMed ID: 30183397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined deficiency of apolipoprotein C-II and lipoprotein lipase in familial hyperchylomicronemia.
    Stalenhoef AF; Casparie AF; Demacker PN; Stouten JT; Lutterman JA; van 't Laar A
    Metabolism; 1981 Sep; 30(9):919-26. PubMed ID: 7266379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.
    Kohan AB
    Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):119-25. PubMed ID: 25692924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia.
    Prohaska TA; Alexander VJ; Karwatowska-Prokopczuk E; Tami J; Xia S; Witztum JL; Tsimikas S
    J Clin Lipidol; 2023; 17(3):406-411. PubMed ID: 37164837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II.
    Fojo SS; Brewer HB
    J Intern Med; 1992 Jun; 231(6):669-77. PubMed ID: 1619390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.